Caricamento...
High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
BACKGROUND: Globally 3.9% of new and 21% of re-treatment tuberculosis (TB) cases are multidrug-resistant or rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor treatment adherence. This study aims to assess the respective contributions...
Salvato in:
| Pubblicato in: | BMC Infect Dis |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5217596/ https://ncbi.nlm.nih.gov/pubmed/28061832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-016-2171-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|